Hampel, Harald http://orcid.org/0000-0003-0894-8982
Cummings, Jeffrey
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Gao, Peng
Jack, Clifford R. Jr http://orcid.org/0000-0001-7916-622X
Vergallo, Andrea
Article History
Accepted: 28 May 2021
First Online: 8 July 2021
Competing interests
: H. H. is an employee of Eisai and serves as Senior Associate Editor for the journal <i>Alzheimer’s & Dementia</i>. He has not received any fees or honoraria since May 2019; before May 2019, he was a consultant and received lecture fees from Servier, Biogen and Roche, research grants from Pfizer, Avid and MSD Avenir (paid to the institution), travel funding from Eisai, Functional Neuromodulation, Axovant, Eli Lilly and Company, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics, consultancy fees from Qynapse, Jung Diagnostics, Cytox, Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics and Functional Neuromodulation, and participated in the scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and Company, Cytox, GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics. He is co-inventor in the following patents as a scientific expert and has received no royalties: In Vitro Multiparameter Determination Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders (patent no. 8916388); In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases (patent no. 8298784); Neurodegenerative Markers for Psychiatric Conditions (publication no. 20120196300); In Vitro Multiparameter Determination Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders (publication no. 20100062463); In Vitro Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders (publication no. 20100035286); In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases (publication no. 20090263822); In Vitro Method for the Diagnosis of Neurodegenerative Diseases (patent no. 7547553); CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases (publication no. 20080206797); In Vitro Method for the Diagnosis of Neurodegenerative Diseases (publication no. 20080199966); Neurodegenerative Markers for Psychiatric Conditions (publication no. 20080131921); and Method for Diagnosis of Dementias and Neuroinflammatory Diseases Based on an Increased Level of Procalcitonin in Cerebrospinal Fluid (publication no. US Patent 10921330). J. C. has provided consultation to Acadia, Actinogen, Alkahest, Alzheon, AnnovisBio, Avanir, Axsome, BiOasis, Biogen, Cassava, Cerecin, Cortexyme, Cytox, Diadem, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Maplight, Merck, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant, Third Rock, and United Neuroscience pharmaceutical and assessment companies. He has stock options in ADAMAS, MedAvante, QR pharma/AnnovisBio, and BiOasis. K. B. has served as a consultant, on advisory boards or on data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is part of the GU Ventures Incubator Program. C. R. J. serves on an independent data monitoring board for Roche and is a speaker for Eisai but receives no personal compensation from any commercial entity. P. G. is an employee of Eisai. A. V. is an employee of Eisai. He has not received any fees or honoraria since November 2019. Before November 2019, he received lecture honoraria from Roche, MagQu LLC and Servier.